Loeb & Loeb LLP is proud to sponsor the American Conference Institute’s (ACI) 11th Summit On Biosimilars taking place from September 23-24, 2020 where senior counsel Ryan Hagglund will be speaking on the panel "Pre-Suit Exchanges and the BPCIA Tango: Production, Timing, and the Notice of Commercial Marketing".
About the event:
As the number of FDA-approved biosimilar products continues to grow, the need for a solid guiding framework becomes more critical than ever before. While the stakeholders wait for finality on the rules governing significant matters like interchangeability, substitution and equivalency, it is clear that biosimilars will remain a top priority for the FDA. The biosimilars market continues to maintain momentum as we head into 2020, but questions remain as to whether the U.S. market will catch up with Europe and whether biosimilars will provide their intended cost-savings. Join the “who’s who” of the biosimilars and innovator biologics industries as they gather in Boston for ACI’s 2020 Summit on Biosimilars & Innovator Biologics, and contemplate these and other probing questions.
For more information, including how to register, please visit the event website.